ALZHEIMER’S RESEARCH

Solanezumab

Though it is not yet available to the general public, an experimental medication named Solanezumub looks promising in late-stage testing that was found to improve the cognitive skills of patients with mild Alzheimer’s by 34 percent. The drug is designed to remove the ‘sticky’ protein beta-amyloid from the brain, which is believed to be one of the causes of Alzheimer’s symptoms.